Abstract:The lack of predictive preclinical models is a fundamental barrier to translating knowledge about the molecular pathogenesis of cancer into improved therapies. Insertional mutagenesis (IM) in mice is a robust strategy for generating malignancies that recapitulate the extensive inter- and intra-tumoral genetic heterogeneity found in advanced human cancers. While the central role of "driver" viral insertions in IM models that aberrantly increase the expression of proto-oncogenes or disrupt tumor suppressors has been appreciated for many years, the contributions of cooperating somatic mutations and large chromosomal alterations to tumorigenesis are largely unknown. Integrated genomic studies of T lineage acute lymphoblastic leukemias (T-ALLs) generated by IM in wild-type (WT) and Kras mutant mice reveal frequent point mutations and other recurrent non-insertional genetic alterations that also occur in human T-ALL. These somatic mutations are sensitive and specific markers for defining clonal dynamics and identifying candidate resistance mechanisms in leukemias that relapse after an initial therapeutic response. Primary cancers initiated by IM and resistant clones that emerge during in vivo treatment close key gaps in existing preclinical models, and are robust platforms for investigating the efficacy of new therapies and for elucidating how drug exposure shapes tumor evolution and patterns of resistance. Author summary A lack of predictive cancer models is a major bottleneck for prioritizing new anti-cancer drugs for clinical trials. We comprehensively profiled a panel of primary mouse T lineage leukemias initiated by insertional mutagenesis and found remarkable similarities with human T-ALL in regard to overall mutational burden, the occurrence of specific somatic mutations and large chromosomal alterations, and concordant gene expression signatures. We observed frequent duplication of the Kras oncogene with loss of the normal allele, which has potential therapeutic implications that merit further investigation in human leukemia and in other preclinical models. Mutations identified in mouse leukemias that relapsed after in vivo treatment with signal transduction inhibitors were also observed in relapsed human T-ALL, indicating that this model system can be utilized to investigate strategies for overcoming intrinsic and acquired drug resistance. Finally, preclinical models similar to the one described here that are characterized by a normal endogenous tumor microenvironment and intact immune system will become increasingly important for testing immunotherapy approaches for human cancer.

Chemically induced mutations in a MutaMouse reporter gene inform mechanisms underlying human cancer mutational signatures

Characterizing Benzo[a]pyrene-induced lacZ mutation spectrum in transgenic mice using next-generation sequencing

From tobacco smoking to mutational signature: the role of epigenetic changes in human cancers

Next generation sequencing of benzo(a)pyrene-induced lacZ mutants identifies a germ cell-specific mutation spectrum

Real-Time Resolution Of Point Mutations That Cause Phenovariance In Mice

Convergent genetic aberrations in murine and human T lineage acute lymphoblastic leukemias.

Chemical-induced Cancer Incidence and Underlying Mechanisms in Fen1 Mutant Mice

Paternal exposure to benzo(a)pyrene induces genome-wide mutations in mouse offspring

Transgenic Murine Models of Human Cancer: Bridging the Gap from Mouse to Man

Assessment of in vivo chemical mutagenesis by long-read sequencing

A high-throughput next-generation sequencing-based method for detecting the mutational fingerprint of carcinogens

If you give a mouse a mutation: comparing the therapeutic utility of renowned mouse models of human cancers

The interplay between dormant mutated cells and tumor promotion by chronic tissue damage in determining cancer risk

Transposon Insertional Mutagenesis In Mice Identifies Human Breast Cancer Susceptibility Genes And Signatures For Stratification

N-Nitrosodimethylamine investigations in MutaTMMouse define point-of-departure values and demonstrate less-than-additive somatic mutant frequency accumulations

Whole Genome Sequencing Analysis of Model Organisms Elucidates the Association Between Environmental Factors and Human Cancer Development

A Quantitative Toxicogenomics Assay for High-throughput and Mechanistic Genotoxicity Assessment and Screening of Environmental Pollutants

Large-scale Screening of Disease Model Through ENU Mutagenesis in Mice

Discriminating Spontaneous From Cigarette Smoke and THS 2.2 Aerosol Exposure-Related Proliferative Lung Lesions in A/J Mice by Using Gene Expression and Mutation Spectrum Data

Abstract 2440: Cancer driver mutations as quantitative biomarkers of cancer risk interspecies analyses using CarcSeq

Current Strategies for Mutation Detection in Phenotype-Driven Screens Utilising Next Generation Sequencing